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Glycan-dependent binding of galectin-1 to neuropilin-1
promotes axonal regeneration after spinal cord injury
HR Quinta´1, JM Pasquini*,1,4, GA Rabinovich*,2,3,4 and LA Pasquini*,1,4
Following spinal cord injury (SCI), semaphorin 3A (Sema3A) prevents axonal regeneration through binding to the neuropilin-1
(NRP-1)/PlexinA4 receptor complex. Here, we show that galectin-1 (Gal-1), an endogenous glycan-binding protein, selectively
bound to the NRP-1/PlexinA4 receptor complex in injured neurons through a glycan-dependent mechanism, interrupts the
Sema3A pathway and contributes to axonal regeneration and locomotor recovery after SCI. Although both Gal-1 and its
monomeric variant contribute to de-activation of microglia, only high concentrations of wild-type Gal-1 (which co-exists in a
monomer–dimer equilibrium) bind to the NRP-1/PlexinA4 receptor complex and promote axonal regeneration. Our results show
that Gal-1, mainly in its dimeric form, promotes functional recovery of spinal lesions by interfering with inhibitory signals
triggered by Sema3A binding to NRP-1/PlexinA4 complex, supporting the use of this lectin for the treatment of SCI patients.
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Spinal cord injury (SCI), an insult that results in a change either
temporary or permanent in normal motor, sensory or auto-
nomic function, remains a major challenge in biomedicine.1
This pathological process involves the interplay of several
factors, including matricellular proteins and pro-inflammatory
cytokines, which contribute to inhibit axonal regeneration post
lesion. Semaphorin 3A (Sema3A), a soluble member of the
semaphorin superfamily, inhibits axonal regeneration following
SCI by acting on microtubules and actin cytoskeleton.2–5
During neuronal development, Sema3A directs axonal
guidance through binding to the neuronal receptor neuropilin-1
(NRP-1), serving as an anti-attractant molecule for axonal
growth.6,7 Binding of Sema3A to NRP-1 requires the formation
of a complex with PlexinA4, another member of the sema-
phorin family, essential for triggering intracellular signaling
events.8,9 Sema3A ismainly secreted bymeningeal fibroblasts
in the injured area and contributes to inadequate axonal
regeneration after SCI.3,9 Interestingly, expression of Sema3A
in adult intact spinal cord is barely detectable; however, when
the lesion occurs, its levels increase considerably due to
breakdown of meningeal coverings, leading to migration of
Sema3A-expressing fibroblasts to the lesion site and inclusion
of these cells into the glial scar.3 After SCI, descendent motor
tracts and neighboring neurons express distinct components of
the Sema3A signaling pathway, mainly NRP-1 and PlexinA4,
whichmake them sensitive to Sema3A binding and inhibition of
axonal regeneration.4,10–12 Thus, interruption of Sema3A
signaling may lead to axonal regeneration and functional
recovery after SCI.
Galectin-1 (Gal-1), a member of a highly conserved family of
animal lectins, binds to the common disaccharide (Galb1–4)
GlcNAc) on both N- and O-glycans decorating cell surface
glycoconjugates. This lectin exists in a monomer–dimer
equilibrium depending on its relative concentration and
biochemical features of different tissues.13 Within the CNS,
Gal-1 controls proliferation of adult neural progenitor cells,14,15
regulates neurogenesis and promotes functional recovery
after stroke.16 Expression of Gal-1 correlates with the
regenerative potential of spinal motoneurons after SCI.17–19
Recently, we found that Gal-1 prevents neurodegeneration
and promotes neuroprotection in a model of autoimmune
neuroinflammation by promoting microglia deactivation.20
However, in spite of considerable progress, the mechanistic
basis of these findings and their therapeutic implications in a
setting relevant to human SCI remain unexplored.
Here we evaluated the consequences of Gal-1 treatment
in situ in an in vivo model of SCI which allowed the
assessment of full locomotor recovery. We found that high
concentrations of Gal-1 (47 mM), which favor a shift toward
the dimeric form of this protein, promoted full locomotor
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recovery in the SCI model. In contrast to the effects on
microglial deactivation which were observed using either
Gal-1 or amonomericmutant of this lectin lacking dimerization
capacity, neuroregeneration as well as full locomotor recovery
were observed only when lesions were exposed to the dimeric
form of this protein. Mechanistically we show that Gal-1 bound
to the NRP-1/PlexinA4 receptor complex on injured neurons
through a glycan-depending mechanism. This interaction
blocked binding of Sema3A to this receptor complex and
promoted full axonal regeneration, leading to locomotor
functional recovery. Our results highlight the therapeutic
potential of stable dimeric Gal-1 as a feasible therapy for
patients with SCI.
Results
Gal-1 promotes locomotor function recovery after SCI.
To investigate the mechanisms underlying the neuro-
regenerative effects of Gal-1, we studied the role of this
glycan-binding protein in axon regeneration after SCI using a
complete transection model. To avoid spontaneous spinal
reflex self-recovery, analysis of different parameters was
performed at early time periods and finalized on day 7 post
SCI. We analyzed the behavior of Lgals1 / (galectin-1-
deficient) and wild-type (WT) mice subjected to SCI and
further treated either with WT recombinant Gal-1 (co-existing
in a dimer–monomer equilibrium) or with vehicle control
(PBS). To assess mouse hindlimb movement, we used the
21-point open field Basso–Beattie–Bresnahan (BBB) loco-
motor rating scale (BBB scoring) (Figure 1a). All mice
suffered hindlimb paralysis immediately after transection.
Whereas hindlimb paralysis showed virtually no recovery in
vehicle-treated Lgals1 / mice (BBB score: 0.35±0.3),
Lgals1 / mice treated with 0.5 or 1 mg/ml Gal-1 showed a
significant increase in BBB score (12±0.5 and 16±0.7,
respectively) (Po0.001). A representative video sequence of
vehicle-treated Lgals1 / mice illustrated no significant
movement in hindlimbs and no weight support. These mice
were unable to keep their balance and dragged their
abdomen and tail. Moreover, they showed spinal column
hunching and dorsal placement of a fully extended and
immobile paw, as well as a total disability to keep on top of
the bridge-shaped metal grid (Figure 1b and Supplementary
Figure S1). In contrast, Lgals1 / mice treated with 1mg/ml
Gal-1 showed a substantial recovery of hindlimb function,
which helped keeping a normal position instead of falling on
one side. These animals showed a locomotor behavior
similar to sham animals, that is, using all four limbs and lifting
their tails. They also exhibited minimal shaking and faster
movements (Figure 1c and Supplementary Figure S2).
Furthermore, the grid-walking apparatus test was performed
to evaluate motor coordination, which depends on descend-
ing motor control and ascending flow of proprioceptive and
tactile information.21,22 These animals showed a low number
of foot fall errors (3±1). Similar results were obtained in
sham animals (Supplementary Figure S3). These results
suggest that an early intervention with Gal-1 is sufficient to
prevent hindlimb loss of function. Remarkably, WT mice
treated with vehicle control displayed significantly higher but
limited BBB score (B4±0.65) than vehicle-treated Lgals1 /
mice (Po0.001, Figure 1a), indicating that the absence of
endogenous Gal-1 prevents recovery of spontaneous motor
function. Vehicle-treated WT mice successfully balanced for
short periods of time, although they remained leaning on one
side. Their self-recovery was mainly evidenced in paw
position during stance by the degree of trunk stability and
the decreased frequency of dorsal stepping (data not
shown). Surprisingly, when comparing treatments with Gal-1
in WT versus Lgals1 / mice, we found similar locomotor
recovery levels using only the highest dose of Gal-1 (1mg/ml)
(BBB score: 14.5±0.9), while a lower dose of this lectin
(0.5 mg/ml) induced significantly less recovery in WT as
Figure 1 Evaluation of mouse hindlimb movements. (a) BBB scoring of Lgals1 / and WT mice treated with 0.5mg/ml or 1mg/ml Gal-1. Values represent the
mean±S.D. of seven independent experiments (n¼ 3 mice per group). ***Po0.001 using one-way ANOVA followed by Tukey’s tests. (b) Representative video images of
injured vehicle-treated-Lgals1 / mice. Yellow arrows show spinal column and tail position. The right images show placement of paw (yellow lines) and tail position.
(c) Representative video images of injured Lgals1 / mice treated with 1mg/ml Gal-1. Green arrows show a complete cycles of hindlimb movement. The yellow arrow in the
same images shows tail position. The right images indicate the paw articulation placement (yellow lines) and also show tail position. (d) The left picture corresponds to a
representative injured Lgals1 / mice treated with 1mg/ml Gal-1 analyzed 7 days post injury. The right picture corresponds to the same animal after retransection and shows
paw and tail position (green and yellow arrows, respectively). The right bar graph shows BBB scoring after 1 and 4 days post retransection. Values represent the mean±S.D.
of three independent experiments (n¼ 5 mice per group). ***Po0.001 using one-way ANOVA followed by Tukey’s tests
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compared with Lgals1 / mice (BBB score: 6±0.8 versus
12±0.5, respectively) (Po0.001, Figure 1a).
To further understand the cellular basis of this neuroregen-
erative effect, we evaluated whether the functional recovery
induced by Gal-1 was a result of axonal regeneration at the
lesion site or whether it was associated to recovery of
autonomous function below the lesion. We retransected the
lesion site 8 days after the first transection, which generated a
loss of recovered locomotor function (Po0.001, Figure 1d).
The BBB score dropped to zero and remained at this level for
42 weeks. These findings suggest that functional recovery
observed in the Gal-1-treated group was most likely caused
by axonal regeneration across the lesion site rather than a
compensatory response below the site.
Early Gal-1 treatment leads to reduced scar formation
and microglial–astroglial deactivation. Treatment with
Gal-1 induced a dose-dependent decrease in scar size in
both WT and Lgals1 / mice. In contrast, vehicle-treated
WT mice showed a significant but limited reduction in scar
size, which was absent in vehicle-treated Lgals1 / mice
(Po0.001, Po0.01, Figure 2a). Illustrating this phenom-
enon, a computer-generated image showed the lesion site in
red due to an increased number of pixels on blue background
as a consequence of inflammation.
Glial scar formation is in part dependent upon the post-
injury inflammatory response, including the contribution of
rapidly dividing activated microglia, blood-derived macro-
phages and reactive astrocytes, although it also relies on the
degree of cell death at the lesion site.23–27 Given the
relevance of this response in the recovery of locomotor
functions, we analyzed the expression of ED1 (a marker of
activated microglia), glial fibrillary acidic protein (GFAP; an
astrocyte marker) and nestin (a marker of reactive astrocytes)
on spinal cord sections from Gal-1-treated Lgals1 / mice.
Gal-1 treatment induced no significant changes in the number
of ED1-positive cells at the lesion site (Figure 2b). However, a
strong decrease was observed in the surrounding lesion area
in mice treated with 0.5 or 1 mg/ml Gal-1, suggesting a less
aggressive post-injury inflammatory response. Of note,
destruction of downstream tissue in the spinal cord treated
with vehicle control was only observed in Lgals1 / mice,
whereas expression of ED1 could only be detected in the
upstream area.
No significant increase in GFAP-positive cells was
observed in laminectomy areas under control conditions (data
not shown). However, Gal-1 treatment induced profound
changes in the phenotype of GFAP-positive cells. Re-
expression of nestin intermediate filaments was observed in
reactive astrocytes,28 which were selectively distributed in
areas surrounding the lesion but not in the lesion itself. Gal-1
treatment induced sharp alterations in the morphology of
nestin-positive cells, revealing a strong reduction in cellular
processes. Quantitative support was obtained through the
Figure 2 Evaluation of scar size and microglial–astroglial response induced by Gal-1. In all representative images, the left side is cranial. (a) Spinal cord scar size in 0.5 or
1mg/ml Gal-1-treated-Lgals1 / and WT mice. Pictures show scar localization delimited by white dotted line. Also, in the bottom left corner of each picture, a spectrum graph
generated with the Lut function of Fiji image processing software emphasizes higher signal in red and lower signal in blue. Calibration is shown on the right band (0–255
colors). Quantitative analysis is shown in bar graph below. Values represent the mean±S.D. of seven independent experiments (n¼ 3 mice per group). ***Po0.001,
**Po0.01 using one-way ANOVA followed by Tukey’s tests. (b) Triple staining shows expression of ED1 and nestin at the lesion site and gray matter (dotted frames 1 and 2)
with vehicle or 1 mg/ml Gal-1 (counterstained with DAPI (4,6-diamidino-2-phenylindole)) . Scale bars: 250mm for  4; 150mm for  20. Quantitative analysis is shown in the
right bar graph. Values represent the mean±S.D. of six independent experiments (n¼ 3 mice per group). ***Po0.001, NS¼ not significant, using one-way ANOVA followed
by Tukey’s tests. (c) The figure shows the Z-projection image of nestin-positive cells at the lesion site (dotted frame 2), acquired using confocal Z-reconstruction microscopy.
Scale bar, 50mm. (d) Filament plot was performed for each image, and quantification is shown on the right bar graph. Values represent the mean±S.D. of six independent
experiments (n¼ 3 mice per group). **Po0.01 using unpaired t-test
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assessment of branches and terminals as well as the length of
these processes (Po0.01, Figures 2c and d).
Treatment with Gal-1 enhances regeneration of injured
axons. The degree of functional recovery following SCI
depends on the reorganization of neuronal circuits by
synaptic plasticity and collateral sprouting of injured and
healthy descending tracts.29,30 To examine the effect of
Gal-1 treatment in the regeneration of injured axons, we
performed immunohistochemical analysis using the specific
neuronal marker bIII-tubulin and the axonal markers Neuro-
filament-M (NF-M) and axonal microtubule-stabilizing protein
Tau-1.31 The grey matter of vehicle-treated Lgals1 / mice
exhibited no neurite regeneration at the epicenter of the
lesion site (Figure 3a) and evidenced no significant differ-
ences with vehicle-treated WT mice, suggesting that
endogenous Gal-1 did not induce neurite regeneration. In
contrast, Gal-1-treated Lgals1 / mice exhibited a signifi-
cant and dose-dependent increase in the regenerated area
of the lesion (0.8 and 1mm2 using 0.5 and 1mg/ml Gal-1,
respectively) as compared with vehicle-treated Lgals1 /
mice (Po0.001, Figures 3b–d). When results were
expressed as the percentage of neurite regeneration, only
Gal-1-treated animals exhibited a significant increase (67
and 73%, using 0.5 and 1mg/ml Gal-1, respectively) at the
lesion site (Figure 3e). Interestingly, in the upstream area of
Lgals1 / mice treated with 1 mg/ml Gal-1, gray matter
occupation by motoneurons reached levels similar to those
observed in sham mice (Figure 3f).
When the downstream area was analyzed, the motoneurons
in gray matter were more preserved in Lgals1 / mice
treated with 1mg/ml Gal-1, as compared with vehicle-treated-
Lgals1 / mice, almost reaching sham levels. In this area, a
significant number of motoneurons was observed in vehicle-
treated WT mice relative to vehicle-treated Lgals1 / mice,
suggesting the activation of a homeostatic circuit triggered by
endogenous Gal-1 (Supplementary Figure S4). To further
characterizemotor circuits, we performed a retrograde tracing
Figure 3 Neurite regeneration induced by Gal-1. In all representative images, the left side is cranial. (a) Triple staining in spinal cord from mice treated with vehicle at the
lesion site (dotted line area marked by an asterisk) with bIII-tubulin, GFAP and DAPI (4,6-diamidino-2-phenylindole). The free floating inset shown in the right picture highlights
the lesion site (black arrow) and the loss of downstream tissue (black asterisk). Images below correspond to magnification of dotted frames of lesion site and gray matter
(frames 1 and 2). Panels (b) and (c) correspond to tissue from animals treated with 0.5 and 1mg/ml Gal-1, respectively. Images below correspond to magnification of dotted
frames 1 and 2. Scale bars: 250mm for  10; 150 mm for  20. (d and e) Bar graphs show quantification of neurite regeneration areas also depicted as percentage. (f) Bar
graph shows quantification of gray matter area occupied by motoneurons upstream of the lesion site. Values represent the mean±S.D. of six independent experiments (n¼ 3
mice per group). ***Po0.001 using one-way ANOVA followed by Tukey’s tests
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assay in which the motor circuits afferent to muscle were
analyzed. We confirmed the preservation of lumbar
motoneurons and their functional axons in Gal-1-treated
Lgals1 / mice as cholera toxin b-subunit (CTB) label cells
directly projecting to muscle (Figure 4).
When the number of regenerated axons was analyzed at
the epicenter of the lesion site, we only found a few fragments
of neurofilament-positive axons in vehicle-treated Lgals1 /
mice. In contrast, we observed a significant increase in
neurofilament-positive axons as well as an increase in Tau-1
expression in Gal-1-treated Lgals1 / mice (Po0.001,
Figures 5a–c). Importantly, we only found downstream tissue
degeneration in vehicle-treated Lgals1 / mice.
Assessment of regeneration in the white matter showed
that treatment of Lgals1 / mice with Gal-1 induced an
increase in the percentage of the area occupied by bIII-
tubulin-positive axons (see Figures 6a and c). Accordingly, a
dose-dependent increase in the number of regenerated NF-
M-positive axons was observed in Lgals1 / mice treated
with Gal-1 as compared with vehicle-treated Lgals1 / mice
(P 0.02, Po0.001, Figures 6b and d). Of note, no significant
differences were observed between Lgals1 / mice treated
with the highest dose of Gal-1 and sham Lgals1 / mice.
Collectively, these results indicate substantial axonal regen-
eration induced by Gal-1 in descending and ascending tracts
of the lesion site.
Gal-1 inhibits Sema3A binding to the NRP-1–PlexinA4
complex. To gain insight into the molecular mechanisms
underlying this neuroregenerative effect, we hypothesized
that Gal-1 could bind to NRP-1–PlexinA4 (Sema3A-complex
receptor) and interfere with Sema3A binding, thus blocking
its inhibitory effect on axonal regeneration. Longitudinal
slices (30 mm) obtained from Lgals1 / mice treated with
Gal-1 or vehicle control were incubated in vitro with Gal-1 or
with biotin-tagged Gal-1 (50mM). In these slices, we
assessed cellular distribution of NRP-1, Gal-1 and Sema3A
(Figure 7). Upstream of the lesion, a motoneuron pheno-
typically normal showed that NRP-1 flanked axonal growth.
NRP-1 accumulation is indicated by yellow arrows, while
axonal growth is depicted with a white dotted line towards
white matter (yellow asterisk). In the area adjacent to the
lesion – above the yellow dotted line – a neuron is shown
where Gal-1 is absent, showing NRP-1 accumulation close to
the axon and blocking cone growth (yellow arrows). On the
opposite side, ectopic and truncated sprouting indicates
failure of regeneration (blue arrow). This sprouting effect was
in agreement with studies where lesioned neurons were
capable, depending on environmental cues, of regenerating
axon-like structures, even from pre-existing dendrites
opposing the original axon.32–34 In contrast, the lesion
area showed neurons with considerable uptake of exo-
genous Gal-1 accompanied by spread of NRP-1 and axonal
Figure 4 Quantification of CTB-positive cell bodies corresponding to motor circuits afferent to the muscle. Vehicle- and Gal-1-treated Lgals1 / mice showed SCI
followed by axonal tracing with CTB-Alexa 488 injections into the gastrocnemius muscle/sciatic nerve site. The left panels are representative images taken from the lumbar
section, where the left side is cranial. The bar graph shows the number of motoneurons in each group that uptake CTB. Values represent the mean±S.D. of four independent
experiments (n¼ 3 mice per group). ***Po0.001 and NS¼ not significant using one-way ANOVA followed by Tukey’s tests. The bottom right panels 1 and 2 show a confocal
magnification of CTB-positive cell bodies from Gal-1-treated Lgals1 / mice with a specific motoneuron marker, HB9, and specific neuronal marker, bIII-tubulin. Scale bars:
250mm for  10; 100mm for  40. 20mm for 63X
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regeneration (yellow arrows) (Figure 7a). A computer-
generated 3-D image, obtained from Z-stack scanning of
cells immunostained for Gal-1 and NRP-1, showed that Gal-1
bound to the surface of injured neurons. In addition, a
quantitative correlation analysis using Mander’s algorithm
showed that 75% NRP-1 clusters had, in turn, a Gal-1 cluster
in the vicinity of their focal plane and that their colocalization
rate was almost 50% (Figure 7b).
To evaluate the ability of Gal-1 to interrupt the Sema3A
pathway, we compared Sema3A immunoreactivity in the
lesion area of vehicle- or Gal-1-treated-Lgals1 / mice.More
than 80% Sema3A immunoreactivity was observed adjacent
to the lesion site in neurons of vehicle-treated-Lgals1 /
mice, which showed truncated axons (thick blue arrows)
(Figure 7c). Strikingly, as a result of Gal-1 treatment,B80%of
neurons showing high Gal-1 uptake (yellow arrows) and axon
regeneration (white dotted line) showed no Sema3A uptake.
Interestingly, the area inside the lesion without cellular bodies
(indicated by a yellow asterisk) was surrounded by truncated
axons (thin blue arrows) with Sema3A immunoreactivity and
absence of Gal-1 uptake. Of note, a bIII-tubulin immuno-
reactive neuron body showing non-regenerated axons (thick
blue arrow) co-localized with Sema3A (Figure 7c). Further-
more, immunoreactivity of the Sema3A-coreceptor PlexinA4
and its co-localization with Gal-1 and bIII-tubulin were
evaluated in longitudinal slices from Lgals1 / mice treated
Figure 5 Quantification of neurofilament-positive axons and Tau-1 expression in Gal-1-treated Lgals1 / mice. In all representative images, the left side is cranial.
(a) Double staining, in spinal cord from mice treated with vehicle or Gal-1 at the lesion site, with NF-M and GFAP. Figures below correspond to magnification of dotted frames at
the epicenter of lesion site. 3D projection corresponds to confocal z-series. The axonal mask was performed using Neuron J plug-in from Fiji program. (b) Bar graph shows the
number of regenerated axons at the epicenter of the lesion site. Values represent the mean±S.D. of five independent experiments (n¼ 3 mice per group). ***Po0.001 using
unpaired t-test. (c) Single staining with Tau-1. The image shows the expression of Tau-1 at the epicenter of lesion site; the inset shows magnification of the white dotted frame.
The expression analysis was performed using 3D surface plot plug-in from Fiji program. Scale bars: 250mm for  10; 150mm for  20; 50mm for  40
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with 1 mg/ml Gal-1. As shown in the 3-D image, Gal-1 bound to
the surface of injured neurons. In addition, a quantitative
correlation analysis using Mander’s algorithm showed similar
results to those corresponding to NRP-1 (Supplementary
Figure S5). These results suggest that Gal-1 can interact with
the receptor NRP-1–PlexinA4 complex and displaces
Sema3A binding.
A monomeric Gal-1 mutant (M-Gal-1) induces neuro-
protection through microglial deactivation but fails to
induce neuroregeneration. Given the different biological
activities of monomeric versus dimeric Gal-1 species, we
used a Gal-1 mutant (M-Gal-1), which exists in a monomeric
form even at high concentrations.35 M-Gal-1 treatment in
Lgals1 / mice induced a similar locomotor behavior than
treatment with vehicle control in WT mice showing a BBB
score of B4±0.49 (Supplementary Figure S6a). Both
groups evidenced a limited capacity to keep on the top of
the bridge-shaped metal grid by balancing on their front
limbs, with little use of their tails and no involvement of their
hindlimbs (Supplementary Figures S6b–e). Moreover, these
mice had a significantly higher but limited BBB score
compared with that of vehicle-treated Lgals1 / mice and
strikingly lower than the BBB score attained in Gal-1-treated
Lgals1 / mice (16±0.7).
In agreement with these findings, M-Gal-1 induced a
significant reduction in scar size compared with treatment
with vehicle control, although slighter than that induced byWT
Gal-1 (Supplementary Figure S7). Concomitantly, when ED1-
positive cells were evaluated, treatment with M-Gal-1 induced
no significant changes at the lesion site but a significant
decrease in the upstream and downstream areas (Figure 8a).
Interestingly, the decrease induced by M-Gal-1 was lower in
the downstream than in the upstream area, suggesting
different capacities of monomeric versus dimeric forms of
this lectin to deactivate microglia. Moreover, M-Gal-1-treated-
Lgals1 / mice displayed higher nestin immunoreactivity
with greater process arborization as compared with Gal-1-
treated Lgals1 / mice. These results were quantitatively
supported by the evaluation of branches, terminals and length
Figure 6 White matter axonal regeneration at the lesion site in Lgals1 / mice treated with Gal-1. In all representative images, the left side is cranial. (a) Double staining
with bIII-tubulin and DAPI (4,6-diamidino-2-phenylindole). Left figure corresponds to sham mice and shows white matter area occupied by axons. The following figures display
changes in the area occupied by regenerated axons in white matter at the lesion site in vehicle- or Gal-1-treated-Lgals1 / mice. (b) Single staining with NF-M. 3D projection
corresponds to confocal z-series. (c) Bar graph shows the percentage of white matter area occupied by bIII-tubulin-positive axons at the lesion site. (d) Bar graph shows
quantification of regenerated NF-M-positive axonal tracts. Values represent the mean±S.D. of seven independent experiments (n¼ 3 mice per group). ***Po0.001,
*P¼ 0.0277, NS¼ not significant, using one-way ANOVA followed by Tukey’s tests. Scale bars: 1 mm for  4; 50mm for  20; 100mm for  40
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of processes (Figures 8b and c). We evaluated the neurite
regeneration induced by M-Gal-1 using bIII-tubulin as a
specific marker (Figure 8d). In contrast to the sharp
regenerative effect obtained with WT Gal-1, M-Gal-1 did not
induce neuroregeneration, as no immunoreactive staining
was detected for bIII-tubulin at the epicenter of lesion site
(Figure 8e). On the other hand, both upstream and down-
stream areas (Figures 8f and g) displayed bIII-tubulin-positive
motoneurons with normal phenotype, similar to those
observed with WT Gal-1, which could be the result of
deactivation of microglia. When the percentage of descending/
ascending axons in the white matter at the lesion site was
evaluated (Figure 8h), a significant decrease was observed
when treatment was performed with M-Gal-1 as compared
with the WT lectin. These results are similar to the findings
observed after treatment with vehicle control. These results
suggest that M-Gal-1 has no significant capacity to induce
axonal regeneration. Additionally, cellular distribution of NRP-1
in the lesion area of M-Gal-1-treated mice was evaluated.
Surprisingly, Gal-1 immunoreactivity was not observed in
these samples, indicating that M-Gal-1 has no ability to bind
neuronal targets. Moreover, M-Gal-1-treated lesions showed
neurons with NRP-1 accumulation close to truncated axons
(yellow arrows) (Figure 8i).
To further confirm these interactions at the biochemical
level, immunoprecipitation assays were performed with total
cell lysates obtained from the lesion site (plus 1 mm up and
down) 1 day after SCI from Lgals1 / mice treated with WT
Figure 7 Localization of NRP-1, Gal-1 and Sema3A in neurons from vehicle- or Gal-1-treated-Lgals1 / mice. (a) Confocal representative images showing neurons in
three different areas of the spinal cord and in different magnification ( 40 in top panel and  63 in bottom panel). (b) Figure shows a computer-generated 3D image of
NRP-1 (green) and Gal-1 (red) clusters localized on the neuron body (dotted black frame in  63 right image of panel (a). The right panel shows a quantitative correlation
analysis using Mander’s algorithm, as well as a quantitative colocalization rate analysis. Data are representative of four independent experiments (n¼ 3 mice per group). (c) A
representative triple staining with bIII-tubulin, Sema3A and Gal-1 shows neurons in the lesion area in vehicle- (left) or Gal-1-treated Lgals1 / mice (right). The quantification
is shown in the bar graphs on the right. Values represent the mean±S.D. of five independent experiments (n¼ 3 mice per group). Scale bar, 20mm
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or M-Gal-1. NRP-1-immunoprecipitates obtained from Gal-1-
treated-Lgals1 / mice showed the presence of immuno-
reactive bands for NRP-1 (only when NRP-1 antibody was
used) and Sema3A-co-receptor PlexinA4, which suggests
that the whole Sema3A receptor complex was pulled down.
Remarkably, these immunoprecipitates were also positive for
Gal-1, supporting the formation of a Gal-1-NRP-1/PlexinA4
complex during neuroregeneration (Figure 9a). However,
immunoprecipitates from M-Gal-1-treated mice showed posi-
tive immunoreactivity only for Sema3A but not for Gal-1
(Figure 9b). These results indicate that Gal-1 in its monomeric
form has no capacity to interfere with Sema3A binding to the
NRP-1–PlexinA4 complex. To further evaluate whether Gal-1
binding to NRP-1 involves glycosylation-dependent inter-
actions, we performed similar experiments using NRP-1-
immunoprecipitated lysates purified from Gal-1-treated
Lgals1 / mice following incubation with PNGase-F to
release N-glycans. Results showed the appearance of a
new 105 kDa protein band corresponding to NRP-1, which
could not bind to Gal-1 as a consequence ofN-glycan removal
(Figure 9c).
In order to confirm whether Gal-1 interferes with the
interactions between Sema3A and the NRP-1–PlexinA4
complex, we evaluated these molecules in NRP-1 immuno-
precipitates from vehicle- and Gal-1-treated Lgals1 / mice.
Quantitative analysis showed a significant decrease in
Sema3A binding induced by Gal-1 treatment, while NRP-1
expression remained at the same levels in both conditions
(Figure 9d), suggesting that Gal-1 may act by inhibiting
Sema3A binding to the NRP-1-PlexinA4 complex. To confirm
the specificity of these interactions, we then immunoprecipi-
tated Gal-1 and checked for co-precipitation of NRP-1.
Results confirmed Gal-1–NRP-1 interactions, and examina-
tion of the whole gel confirmed the absence of other potentially
relevant bands (Figure 9e). These results support the role of
Gal-1 as one of the main NRP-1 binding partners during
axonal regeneration. Notably, the anti-Gal-1 polyclonal anti-
body recognized a 14.5-kDa protein band corresponding to
M-Gal-1, which rules out the possibility that the antibody could
not recognize Gal-1 in its monomeric form. As an additional
control, immunoreactivity of PlexinA4, Sema3A and NRP-1
antibodies was tested in total cell lysates (Figure 9f).
Remarkably, when motor recovery was evaluated following
administration of the Gal-1-N46D mutant lacking carbo-
hydrate-binding activity, we found no considerable recovery
of the motor function in these mice, which showed a BBB
score ofB0 (Figures 10a–e). These results are in accordance
with a complete absence of axonal regeneration and marked
Sema3A immunoreactivity in the injured neurons at the lesion
site (Figure 10f). Collectively, our data show that WT Gal-1
(which occurs in a dimer–monomer equilibrium) recognizes
the NRP-1–PlexinA4 complex through glycan-dependent
mechanisms, displaces Sema3A binding and promotes
neuroregeneration and repair (Supplementary Figure S8).
Discussion
The mechanisms underlying full locomotor recovery following
SCI remain poorly understood. We have identified a role for
Gal-1 as a novel agent capable of interrupting the Sema3A
pathway in vivo by directly binding to the NRP-1/PlexinA4
receptor complex via glycan-dependent mechanisms. Our
findings demonstrate that Gal-1 induced full locomotor
functional recovery and that an early intervention with this
lectin was sufficient to prevent hindlimb loss of function after
SCI. These effects were accompanied by a decrease in scar
size, reflecting microglial–astroglial deactivation. Recovery
was evidenced by determination of BBB locomotor rating
scale, where mice treated with Gal-1 reached the late
recovery stage (forelimb and hindlimb coordination). These
results correlated with a greater number of regenerated axons
in the gray matter, as well as striking axonal regeneration in
the whitematter, within and across the lesion site. Importantly,
after SCI, the descendent axonal tracts axotomized
expressed NRP-1 and PlexinA4, becoming sensitive to the
negative regulatory effects of Sema3A. In this regard,
previous studies showed expression of Sema3A within the
transected spinal cord that was upregulated at the lesion site,
peaking within 1 and 2 weeks after the injury.36 Because of
these particular kinetics, we propose that Gal-1 treatment
should take place within a temporal window where its
interactions with the NRP-1/PlexinA4 complex could lead to
inhibition of Sema3A binding, allowing axonal regeneration of
these tracts.
Although Gal-1 could function through other non-
overlapping mechanisms, it is unlikely that the coordinated
locomotor behavior observed was due to long axonal tract
regeneration from cortex to the lower motoneuron occurring in
such a short time period. The possible mechanism implicated
is the arrangement of intraspinal neural circuits by the local
axons regenerated most probably from interneurons, which
make signal relay and synaptic connections with regenerated
descending axonal tracts as previously described.36,37 Our
findings confirmed preservation of lumbar motoneurons and
their functional axons in Gal-1-treated mice. Finally, a
compensatory response below the lesion site by these lumbar
motoneurons was ruled out by retransection experiments,
which demonstrated that the locomotor recovery was depen-
dent on site-specific regeneration.
Most of the neuroprotective effects of Gal-1 have been
attributed to its immunomodulatory activities.13 Our recent
studies revealed that Gal-1 induces microglia deactivation
and prevents inflammation-induced neurodegeneration.20 In
the present study, we successfully uncoupled the microglial
deactivating effect, which was observed using both WT and
monomeric Gal-1 from the neuroregenerative effect, which
was verified only when high concentrations of WT Gal-1 were
used. This data suggest the importance of dimerization in the
neuromodulatory functions of Gal-1. Accordingly, treatment
with M-Gal-1 induced a poor recovery of locomotor functions
and caused only a minor reduction in scar size. When
neuronal regeneration was analyzed in the lesion area,
M-Gal-1 was unable to promote neuroregeneration. This
result is in line with the failure of M-Gal-1 to interfere with
Sema3A binding to the NRP-1-PlexinA4 complex and the
glycan-dependent nature of these interactions. M-Gal-1
induced only neuroprotection in the upstream or downstream
areas of the lesion, probably as a consequence of microglial
deactivation. In agreement, previous reports have demon-
strated that oxidized Gal-1 – a form that lacks lectin
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activity – promotes neurite outgrowth38 and enhances axonal
regeneration in peripheral and central nerves.39–41 This
axonal regeneration-promoting activity is likely to be para-
crine, as neurite outgrowth induced by oxidized Gal-1 is not
observed in isolated neurons.42 Secreted Gal-1 probably
influences non-neuronal cells surrounding the axons,43
conferring a neuroprotective effect, such as that observed
for M-Gal-1.
Notably, vehicle-treated WT mice reached a BBB score of
B4 and had significant but limited reduction in scar size, two
Figure 8 Microglial–astroglial response, neurite regeneration and NRP-1 cellular localization induced by treatment with monomeric Gal-1 (M-Gal-1). In all representative
images, the left side is cranial. (a) Triple staining with ED1 and nestin at the lesion site (dotted frame 2) and gray matter (dotted frames 1 and 3) with 1 mg/ml of Gal-1 or M-Gal-1
(counterstained with DAPI (4,6-diamidino-2-phenylindole)). Scale bar, 250 mm. Quantitative analysis is shown in the right bar graph. Values represent the mean±S.D. of five
independent experiments (n¼ 3 mice per group). **Po0.01 using one-way ANOVA followed by Tukey’s tests. (b) Figure shows the Z-projection image of nestin-positive cells
at the lesion site (dotted frame 2 from panel (a), acquired using confocal Z-reconstruction microscopy. Scale bar, 50 mm. (c) Filament plot was performed, and quantification is
shown in the right bar graph. Values represent the mean±S.D. of five independent experiments (n¼ 3 mice per group). **Po0.01 using unpaired t-test. (d) Triple staining
with bIII-tubulin, GFAP and DAPI. Scale bar, 250mm. (e–h) The figures are  20 magnification of frames (1–4) in panel (d). Bar graphs show quantification of regeneration
area and percentage of neurite regeneration at the lesion site, percentage of gray matter area occupied by neurons upstream/downstream of the lesion site and white matter
percentage occupied by axons as well as axonal regeneration percentage. Values represent the mean±S.D. of five independent experiments (n¼ 3 mice per group).
***Po0.001 using one-way ANOVA followed by Tukey’s tests. Scale bar, 150mm. (i) Triple staining with bIII-tubulin, NRP-1 and Gal-1 show injured neurons adjacent to the
lesion site (marker with yellow #). Scale bar, 50 mm
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signs of partial recovery which were absent in vehicle-treated
Lgals1 / mice. This striking finding suggests that endo-
genous Gal-1 could allow spontaneous although limited motor
function recovery following SCI. This notion also arises from
the fact that a similar locomotor behavior was obtained in
M-Gal-1-treated Lgals1 / mice. Therefore, endogenous
Gal-1 could be acting mainly as a monomer, consistent with
the physiological concentrations of this lectin, usuallyo7 mM
(the reported dimerization constant).44
Gal-1 was previously described as an endogenous ligand
for NRP-1 expressed in vascular cells, where it stimulates
endothelial cell signaling and function.45 Specific carbo-
hydrate-dependent interactions between Gal-1 and NRP-1
have been demonstrated in cell-free systems using surface
plasmon resonance analysis.45 In our experiments, Gal-1 but
not M-Gal-1 or Gal-1 (N46D) lacking carbohydrate-binding
activity showed robust capacity to regenerate axons via
blockade of Sema3A binding, suggesting that the neuro-
regenerative effects of this lectin are highly dependent on
dimerization and cross-linking of cell surface glycans on
NRP-1. This hypothesis was supported by immunoprecipita-
tion experiments showing that only WT Gal-1, but not M-Gal-1,
binds to the NRP-1/PlexinA4 complex and blocks the Sema3A
pathway. Of note, treatment of NRP-1 immunoprecipitates with
PNGase also prevented Gal-1 binding, thus confirming the
glycosylation-dependent nature of these interactions. Our func-
tional experiments support the relevance of the carbohydrate
recognition domain of this lectin in promoting full locomotor
recovery. Future clinical studies should examine the relevance of
endogenous Gal-1 in patients with neurological disorders.
The relevance of a regulatory factor such as Gal-1 capable
of blocking the Sema3A pathway lies in the fact that it is
expressed earlier than other inhibitors previously described,
such as Nogo-A, myelin-associated glycoprotein and oligo-
dendrocyte-myelin glycoprotein.2–4,46–49 During the past
years, different therapies have been proposed that lead to
axonal outgrowth after SCI such as SM-216289,36 neuro-
trophic factors,50 soluble Nogo receptors,51 chondroitinase
ABC49 or cellular transplantation.52 In particular, SM-216289,
a small-molecule inhibitor, showed inhibition of Sema3A
functions, including growth cone collapse and chemo-
repulsion of neurite extension.53,54 This compound acted on
Sema3A by sterically inducing changes in its structure and
hindering binding of NRP-1. Because Gal-1 not only exerts a
Figure 8 Continued
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full neuroregenerative effect through binding to NRP-1 but
also contributes to deactivating microglia20 and dampening
pathogenic immune cells,55 the coordinated action of these
biological effects may lead to a better restorative process after
medullar lesion.
In summary, the results presented here provide the rational
basis for the use of a stable dimeric form of Gal-1 as a
potential agent for the treatment of human SCI patients.
Methods
Animal and surgical procedures. Male C57BL/6 WT and C57BL/6
Lgals1 / mice (kindly provided by F Poirier, Jacques Monod Institut,
Paris, France) were used between 8 and 10 weeks of age (weight: 23–28 g).
Animal care and treatment were carried out according to guidelines of the
experimental animal care committee of the School of Pharmacy and Biochemistry
of the University of Buenos Aires, Buenos Aires, Argentina. Mice were anesthetized
with ketamine (65 mg per kg body weight) and xilacine (15 mg per kg body weight)
in a 600-ml solution to allow for an anesthetic effect and to prevent a possible
dehydration process. Under a dissecting microscope (Leica EZ4, Wetzlar,
Germany), mice received a complete spinal cord transection at the Th9–Th10
lamina level as previously described.52,56 Briefly, after Th9–Th10 laminectomy, the
dura was opened and the spinal cord was transected using a surgical blade
(Feather, Ribbel International Ltd., New Delhi, India). The severed ends of the cord
were inspected to check for a complete transection. Surrounding muscles and skin
were shut in layers. After the operation, mice were kept warm, placed in an
incubator for 3 h and given manual bladder evacuation twice a day. Food was
Figure 9 Gal-1 binds to NRP-1 through glycan-dependent interactions. NRP-1 and Gal-1 immunoprecipitation (IP) followed by protein co-IP and western blotting analysis.
In all cases, I correspond to immune and NI to non-immune sera. (a and b) Panels show NRP-1 IP of injured spinal cord tissue from Lgals1 / mice treated with 1 mg/ml Gal-1
or M-Gal-1, respectively. (c) Panel shows NRP-1 IP following PNGase F treatment to release N-glycans. Values in bar graphs (a–c) represent the mean±S.D. of three
independent experiments (n¼ 3 mice per group). ***Po0.001 using one-way ANOVA followed by Tukey’s tests. (d) Panel shows NRP-1 IP and Sema3A co-IP of injured
spinal cord tissues from vehicle- or Gal-1-treated-Lgals1 / mice. The bar graph shows the quantitative analysis of Sema3A uptake. Values represent the mean±S.D. of
three independent experiments (n¼ 3 mice per group). ***Po0.001 using one-way ANOVA followed by Tukey’s tests. (e) Gal-1 IP of injured spinal cord tissue from Lgals1 /
mice treated with 1 mg/ml Gal-1. The left panel shows an entire gel (black frame corresponds to immune wells). The right panel shows Gal-1 IP and NRP-1 co-IP. Values in the
bar graph below represent the mean±S.D. of three independent experiments (n¼ 3 mice per group). ***Po0.001 using one-way ANOVA followed by Tukey’s tests.
(f) Panel corresponds to controls. The recombinant WT protein is indicated as Gal-1 and the monomeric variant is indicated as M-Gal-1. Immunoreactivities of PlexinA4,
Sema3A and NRP-1 antibodies were confirmed by immunoblotting on total lysates from spinal cord tissue
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provided on the cage floor, and water bottles were placed within reach. For
retransection studies, surgical processes were performed in the same manner 8
days after the first transection.
Administration of Gal-1 in injured spinal cord. At the time of
transection, 10ml of a recombinant WT Gal-1 form occurring in a monomer–dimer
equilibrium (Gal-1), a stable monomeric mutant (M-Gal-1) or a mutant lacking
carbohydrate-binding activity (Gal-1-N46D) was applied at different concentrations
(0.5–1mg/ml) perpendicularly to the epicenter of the lesion site and in a 451 angle
in both cranial and caudal orientation. In control mice, the same volume of PBS
was instilled. The injection was applied using microcapillary calibrated pipettes
connected to a pump driven through a floor pedal. This process was performed
under a dissecting microscope.
Quantification of astroglial processes and arborization. Quanti-
fication was developed using the Imaris 3D program 6.3.1 IMARIS 6.3.1 (Bitplane
Sci Software, Zu¨rich, Switzerland). Images were obtained using an Olympus
Fluoview 1000 Confocal Microscope (Olympus Headquarters Corporate,
Philadelphia, PA, USA), imported to this program in a calibrated format and
then analyzed using the filament function. To develop this process, the confocal
images were collected in high magnification ( 63 objective, NA, 1.45; oil
immersion) and taking z-series of 40–50 optical slices of airy unit¼ 1 airy-disc at
0.2-mm intervals in accordance with the Nyquist theory (optimum overlapping to
minimize photobleaching). With the same settings, the confocal images were
obtained to develop 3D reconstruction images to perform the 3D colocalization
analysis as previously described.57
Assessment of the spinal cord scar and regenerated axons.
Quantification of the spinal cord scar, lesion and neurite-regenerated areas were
performed using the Fiji program (v.1.45) (NIH; Bethesda, MA, USA) with an area
measurement and a calibration/set scale plug-in for the pre-calibration of each
image. To determine the area occupied by motoneurons upstream/downstream of
the lesion as well as neurite-regeneration area at the lesion site in gray and white
matter, we used an area measurement plug-in with a threshold color plug-in to set
the limits of both structures. Images were measured four times and averaged for
each situation. This process was developed using epifluorescence microscopy
(Olympus BX51, with DP73 Cool Camera). Images were collected at different
magnification levels ( 4,  10,  20 objectives and NA, 0.13, 0.30, 0.50,
respectively). Images were then deconvolved using Huygens compute engine
3.5.2p3 64b (closed platform) or a Parallel Spectral deconvolution plug-in from the
Fiji program (open platform) with Tikhonov method and Laplacian stencil. For this
case, the theoretical Point Spread Function (PSF) was obtained using a Diffraction
PSF 3D plug-in from the Fiji program. For the case of quantification of regenerated
axons, we collected confocal z-series images (30 optical slices of airy unit¼ 1 airy-
disc at 0.25mm intervals using  40 objective) at the lesion site (x/y) and
performed a 3D projection following an automatic axon counter using a threshold-
analyze particle plug-in from the Fiji program.
CTB retrograde tracing and quantification. Retrograde tracing
was performed as previously described58,59 with some modifications. Briefly,
8 days after SCI, animals were injected with 2.5ml of CTB conjugated to
Alexa fluor 488 dye (CTB; 10 mg/ml; Molecular Probes Inc., Eugene, OR, USA)
into the right and left gastrocnemius/sciatic nerve to trace motor circuitry in the
spinal cord. Three days after the tracer injection, mice were killed by perfusion-
fixation and spinal cord lumbar segments were dissected in 45-mm cryostat
longitudinal (cranial to caudal) sections. The quantification of CTB-positive cell
bodies was performed on three serial sections corresponding to ventral horn
segments from each animal in triplicate. The total number of CTB-positive cell
bodies in each sample was calculated as the addition of the count in each serial
section. The counting was performed using the analyze particle plug-in from the
Fiji program.
Behaviour experiments. To examine the effect of Gal-1 on neurological
recovery, we used two behavioral tests on days 0, 5 and 7 post transection and on
days 1, 4 and 15 post retransection. The behavioral assessments were performed
in a flat open field and in a grid-walking apparatus according to the abilities of each
animal. Animals were acclimatized in an open field only for two 10-min cycles 4
days after SCI (1 day before starting the tests).
Open field locomotor test: Mice were evaluated in an open field platform (1 m
length); the recording was carried out in high definition from three different angles
(lateral, above and behind). Animals were assigned a BBB score for hindlimb
movement using the BBB motor rating scale.60
Figure 10 Assesment of hindlimb movements induced by treatment with 1 mg/ml Gal-1-N46D mutant. (a) BBB scoring. Values represent the mean±S.D. of four
independent experiments (n¼ 4 mice per group). ***Po0.001 using one-way ANOVA followed by Tukey’s tests. (b) Representative video images. Yellow arrows show spinal
column and tail positions. (c) Representative images of a mouse on a bridge-shaped metal grid. (d and e) The images indicate placement of paw (yellow lines) and tail position,
respectively. (f) Triple staining with bIII-tubulin, GFAP and DAPI (4,6-diamidino-2-phenylindole). Scale bar, 250mm. The right figures correspond to magnification of dotted
frames 1 and 2. A representative triple staining with bIII-tubulin, GFAP and DAPI (frame 1) and with bIII-tubulin, Sema3A and DAPI (frame 2) show injured neurons at the
lesion site. Scale bars: 150mm for  20; 20mm for  63
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Grid-walking apparatus test: A curved bridge-shaped metal grid (each grid
cell 5 5 cm2) was used to test the animals’ skilled walking. After each trial, 70%
ethanol was used to clean the apparatus. The recording was carried out in high
definition from above. The number of foot fall errors where the hindlimb failed to
grasp a bar and falls between the bars was quantified (0–10 scale) per crossing.
The animals were allowed to walk over the grid three times.
Behavioral tests were carried out in a sound-attenuated room. The analysis for
both tests was developed later by two experimenters who were blind to the
experimental design.
Statistical analysis. Graph-Pad Prism software Version 5.0 (Graph-Pad
software, Inc., La Jolla, CA, USA) was used for data analysis. Results are
presented as mean±S.D. Comparisons were performed using unpaired one-
tailed Student’s t-test or one-way analysis of variance (ANOVA) followed by
Tukey’s post hoc tests, where appropriate.
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